Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 2/2005

01.02.2005 | Review Article

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

verfasst von: Mark G. Kris, Paul J. Hesketh, Jorn Herrstedt, Cynthia Rittenberg, Lawrence H. Einhorn, Steven Grunberg, Jim Koeller, Ian Olver, Sussanne Borjeson, Enzo Ballatori

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.
Literatur
1.
Aapro E, Selak M, Lichinitser D, Santini A, Macciocchi A, Klinik A, Blokhin NN (2003) Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a Phase III trial. Proc ASCO 22:726
2.
Andrews PLR, Davis CJ (1993) The mechanism of emesis induced by anti-cancer therapies. In: Andrews PLR and G.J. Sanger (eds) Emesis in anticancer therapy mechanisms and treatment. Chapman & Hall, London, pp 14–17
3.
Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple- dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969–1975PubMed
4.
Blum RA, Majumdar A, McCrea J, et al (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407–1419CrossRefPubMed
5.
Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMed
6.
Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290–2300CrossRefPubMed
7.
Chevalier B (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26:S33–S36PubMed
8.
Cocquyt V, VanBelle S, Reinhardt RR, Decramer MLA, O’Brien M, Schellens JHM, Borms M, Verbeke L, VanAelst F, DeSmet M, Carides AD, Eldridge K, Gertz BJ (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754-030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835–842CrossRefPubMed
9.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer ME, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105–4111CrossRefPubMed
10.
de Wit R, Herrstedt J, Rapoport B, et al (2004) The oral NK1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. A combined analysis of 2 randomized, placebo-controlled trials. Eur J Cancer 40:403–410CrossRefPubMed
11.
de Wit R, Schmitz PIM, Verweij J, et al (1996) Analysis of cumulative probabilities show that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 14: 644–651PubMed
12.
de Wit R, van den Berg H, Burghouts J, et al (1998) Initial high antiemetic efficacy of ganisetron with dexamethasone is not maintained over repeated doses. Br J Cancer 77:1487–1491PubMed
13.
DeMulder PH, Seynaeve C, Vermorken JB, van LPA, Mols JS, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834–840PubMed
14.
Eisenberg P, Figueroa-Vadillo J, AZamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg SM (2003) improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482CrossRefPubMed
15.
Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15: 330–337CrossRefPubMed
16.
Evidence-Based Medicine WG (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 268:420–425
17.
Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A:35–38
18.
Gandara DR, Roila F, Warr DG, Edelman MJ, Perez EA, Gralla RJ (1998) Consensus proposal for 5-HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Supp Care Cancer 6:237–243CrossRef
19.
Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind placebo-controlled, comparative study. Ann Oncol 6:661–666CrossRef
20.
Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577CrossRefPubMed
21.
Gralla RJ, Tyson LB, Kris MG, Clark RA (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 71:289–301PubMed
22.
Gralla RJ, Popovic W, Strup J, Culleton V, Preston A, Friedman C (1997) Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron versus IV ondansetron. Proc ASCO 16:52b
23.
Gridelli C, Ianniello GP, Ambrosini G, et al (1997) Multicentre, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol 10:395–400
24.
Grunberg SM, Stevenson LL, Russell CA, McDermed JE (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137–1141PubMed
25.
Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796CrossRefPubMed
26.
Grunberg SM, Lane M, Lester EP, Sridhar KS, Mortimer J, Murphy W, Sanderson PE (1993) Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268–272PubMed
27.
Grunberg SM, Hesketh PJ, Carides AD, et al (2003) Relationships between the incidence and control of cisplatin-induced acute vomiting and delayed vomiting: Analysis of pooled data from two phase III studies of the NK-1 antagonist aprepitant. Proc Am Soc Clin Oncol 22:2931a
28.
Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721–728PubMed
29.
Heron JF (1995) Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22:24–30
30.
Herrstedt J (1996) New perspectives in antiemetic treatment. Support Care Cancer 4:416–419PubMed
31.
Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705PubMed
32.
Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613–620PubMed
33.
Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized phase ii study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338–343PubMed
34.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4112–4119CrossRefPubMed
35.
Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14: 2242–2249PubMed
36.
IGAR (1994) Italian Group for Antiemetic Research: Cisplatin-induced delayed emesis: Prognostic factors during three subsequent cycles. Ann Oncol 5:585–589PubMed
37.
IGAR (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805–810PubMed
38.
IGAR (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124–130PubMed
39.
IGAR (1998) Double-Blind, Dose-Finding Study of Four Intravenous Doses of Dexamethasone in the Prevention of Cisplatin-Induced Acute Emesis. J Clin Oncol 16:2937–2942PubMed
40.
IGAR (1999) A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. Anticancer Drugs 5:465–470
41.
Kris MG, Gralla RJ, Clark RA, Tyson LB, OConnell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384PubMed
42.
Kris MG, Gralla RJ, Clark RA, Tyson LB (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6:659–662PubMed
43.
Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42–46PubMed
44.
Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108–114PubMed
45.
Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045–1049PubMed
46.
Kris MG, Roila F, de Mulder PHM, Marty M (1998) Delayed emesis following anticancer chemotherapy. Support Care Cancer 6:228–232CrossRef
47.
Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174–1178PubMed
48.
Louvet C, Lorange A, Letendre F, et al (1991) Acute and delayed emesis after cisplatin-based regimen: Description and prevention. Oncology 48:392–396PubMed
49.
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade LE, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821PubMed
50.
Marty M, Kleisbauer J-p, Fournet P, Vergnenegro A, Carics P, Loria-Kanza Y, Simonetta C, Bruijn KM (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 6:15–21
51.
Matsui K, Fukuoka M, Takada M, Kunsunoki Y, Yana T, Tamura K (1996) Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 73:217–221PubMed
52.
Milano S, Blower P, Romain D, Grelot L (1995) The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J Pharmacol Exp Ther 274:951–961PubMed
53.
Moreno I, Rosell R, Abad A (1992) Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 28A:1344–1347CrossRefPubMed
54.
Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204–2210PubMed
55.
Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242–1248PubMed
56.
Navari RMl, Hesketh PJr (1999) Use of Placebos in Delayed-Emesis Studies (letter). J Clin Oncol 17:338–343PubMed
57.
Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, Huffman DH, Gould JR, Carron G, Ossi M, Anderson EM (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408–2416PubMed
58.
Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:190–195CrossRefPubMed
59.
Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan–Kettering Cancer Center. J Clin Oncol 16:771–778PubMed
60.
Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945–952
61.
Passalacqua R, Cocconi G, Bella M, Monici L, Michiara M, Bandini N, Bacchi M (1992) Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 3:481–485PubMed
62.
Passalacqua R, Cocconi G, Caminiti C, Silingardi V, Bella MA, Bichisao E, Michiara M, Malavasi V, Donati D, DiCostanzo F, Rocca A, DiSarra S, Scaglione F, Fraschini F (1997) Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer. J Clin Oncol 15:2467–2473PubMed
63.
Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxyoyptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036–1043PubMed
64.
Perez EA, Hesketh PJ, Gandara DR (1991) Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol 18: 73–80PubMed
65.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMed
66.
Riviere A, on behalf of the Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967–971PubMed
67.
Roila F, Boschetti E, Tonato M (1991) Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14:238–242PubMed
68.
Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675–678PubMed
69.
Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88–95CrossRefPubMed
70.
Rudd JA, Jordan CC, Naylor RJ (1994) Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 262:R1–R2CrossRefPubMed
71.
Ruff P, Paska W, Goedhals L, Pouiliart P, Riviere A, on behalf of the Granisetron Study Group, Vorolieof D, Bloch, Jones A, Martin L, Brunet R, Butcher, Forster J, McQuade B, on behalf of the Ondansetron and Granisetron Emesis Study Group (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 51:113–118PubMed
72.
Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Pacs D, de Mulder PHM, on behalf of the Ondansetron Study Group (1992) Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 66:192–197PubMed
73.
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fujiwara Y (1989) Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 19:40–44PubMed
74.
Smyth J (1992) Delayed emesis after high-dose cisplatin--the residual problem. In: Proceedings of the Satellite Symposium to the XVII Congress of the European Society for Medical Oncology, Lyon, pp. 24–26
75.
Soukop J, on behalf of the Granisetron Study Group (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177–183PubMed
76.
Soukop M, McQuade B, Hunter E, et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295–304PubMed
77.
Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ (1994) Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin receptor antagonist CP-99,994. Neuropharmacology 33:259–260
78.
Thant M, Pendergras K, Harman G, Modiano M, Martin L, DuBois D, Cramer M, Hahne W (1996) Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin chemotherapy (CCT). Proc ASCO 15:533
79.
Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37:2398–2404CrossRefPubMed
80.
Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer MLA, Rivier A, Thant M, Brestan E, Bui B, Eldridge K, DeSmet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758-298 and MK-869. Cancer 94(11):3032–3041
81.
Van Belle S-P, Stamatakis L, Bleiberg H, Cocquyt FJ, Michel J, de Bruijn KM (1994) Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 5:821–825PubMed
Metadaten
Titel
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
verfasst von
Mark G. Kris
Paul J. Hesketh
Jorn Herrstedt
Cynthia Rittenberg
Lawrence H. Einhorn
Steven Grunberg
Jim Koeller
Ian Olver
Sussanne Borjeson
Enzo Ballatori
Publikationsdatum
01.02.2005
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0699-x

Weitere Artikel der Ausgabe 2/2005

Supportive Care in Cancer 2/2005 Zur Ausgabe

Forthcoming Meetings

Forthcoming Meetings February 2005

Review Article

Antiemetics in children receiving chemotherapy

Review Article

Acute emesis: moderately emetogenic chemotherapy

Review Article

Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement

Review Article

Delayed emesis: moderately emetogenic chemotherapy

Review Article

Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise